Table 3.
Immune effects of ablative therapies (modified from Greten et al63)
| Modality | Activation |
|---|---|
| TACE | IL12p70, IFN-c, IL-17A, IL-2, IL-10, IL-9, IL-22, IL-6, IL-13, IL-4, IL-5, IL-1b, and TNF-a |
| TARE | TNF-a, IL-6, Il-8, oxidative stress markers |
| RFA | Th1 (IL-2, TNF-a, IFN-c), Th2 (IL-4, IL-6, IL-10) |
| Cryo | T cells |
| myeloid-derived suppressor cells | |
| Antigen-presenting cells | |
| TU-associated antigen-derived peptides | |
| Glypican-3-specific CTLs | |
| Immune potentiating antigens in the serum, Ficolin-3 HSP HMGB1 |
|
| MWA | T cell, IL-12 |
| CD3, CD4, CD4+,CD8, CD16, CD25+, CD56, NK, TH17, Tregs | |
| IRE, HifU | T cells |
HMGB1, High-Mobility-Group-Protein B1; HSP, heat shock proteins;MWA, Microwave ablation; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TARE, transarterial radioembolization.